These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 25234810)
1. Update on different aspects of HCV variability: focus on NS5B polymerase. Marascio N; Torti C; Liberto M; Focà A BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S1. PubMed ID: 25234810 [TBL] [Abstract][Full Text] [Related]
2. Current perspective of HCV NS5B inhibitors: a review. Patil VM; Gupta SP; Samanta S; Masand N Curr Med Chem; 2011; 18(36):5564-97. PubMed ID: 22172066 [TBL] [Abstract][Full Text] [Related]
3. Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China. Nie B; Guo Y; Zhang K; Liu J; Yun S Arch Virol; 2020 Sep; 165(9):2013-2020. PubMed ID: 32601956 [TBL] [Abstract][Full Text] [Related]
4. Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naive patients infected with genotypes 1-5. Legrand-Abravanel F; Henquell C; Le Guillou-Guillemette H; Balan V; Mirand A; Dubois M; Lunel-Fabiani F; Payan C; Izopet J Antivir Ther; 2009; 14(5):723-30. PubMed ID: 19704176 [TBL] [Abstract][Full Text] [Related]
5. Characterization of interactions between hepatitis C virus NS5B polymerase, annexin A2 and RNA - effects on NS5B catalysis and allosteric inhibition. Solbak SMØ; Abdurakhmanov E; Vedeler A; Danielson UH Virol J; 2017 Dec; 14(1):236. PubMed ID: 29228983 [TBL] [Abstract][Full Text] [Related]
6. Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine. Ikram A; Obaid A; Awan FM; Hanif R; Naz A; Paracha RZ; Ali A; Janjua HA Antiviral Res; 2017 Jan; 137():112-124. PubMed ID: 27984060 [TBL] [Abstract][Full Text] [Related]
7. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors. Herlihy KJ; Graham JP; Kumpf R; Patick AK; Duggal R; Shi ST Antimicrob Agents Chemother; 2008 Oct; 52(10):3523-31. PubMed ID: 18694956 [TBL] [Abstract][Full Text] [Related]
8. Current race in the development of DAAs (direct-acting antivirals) against HCV. De Clercq E Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613 [TBL] [Abstract][Full Text] [Related]
9. A review on an update of NS5B polymerase hepatitis C virus inhibitors. Varshney J; Sharma PK; Sharma A Eur Rev Med Pharmacol Sci; 2012 May; 16(5):667-71. PubMed ID: 22774409 [TBL] [Abstract][Full Text] [Related]
10. Direct-acting and host-targeting HCV inhibitors: current and future directions. Chatel-Chaix L; Germain MA; Götte M; Lamarre D Curr Opin Virol; 2012 Oct; 2(5):588-98. PubMed ID: 22959589 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden. Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241 [TBL] [Abstract][Full Text] [Related]
12. Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a. Wong KA; Xu S; Martin R; Miller MD; Mo H Virology; 2012 Jul; 429(1):57-62. PubMed ID: 22543048 [TBL] [Abstract][Full Text] [Related]
13. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus. Hang JQ; Yang Y; Harris SF; Leveque V; Whittington HJ; Rajyaguru S; Ao-Ieong G; McCown MF; Wong A; Giannetti AM; Le Pogam S; Talamás F; Cammack N; Nájera I; Klumpp K J Biol Chem; 2009 Jun; 284(23):15517-29. PubMed ID: 19246450 [TBL] [Abstract][Full Text] [Related]
14. Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase. Thueng-in K; Thanongsaksrikul J; Jittavisutthikul S; Seesuay W; Chulanetra M; Sakolvaree Y; Srimanote P; Chaicumpa W MAbs; 2014; 6(5):1327-39. PubMed ID: 25517317 [TBL] [Abstract][Full Text] [Related]
15. Discovery of BMS-961955, an allosteric inhibitor of the hepatitis C virus NS5B polymerase. Zheng BZ; D'Andrea SV; Hanumegowda U; Knipe JO; Mosure K; Zhuo X; Lemm JA; Liu M; Rigat KL; Wang YK; Fang H; Poronsky C; Cutrone J; Wu DR; Arunachalam PN; Balapragalathan TJ; Arumugam A; Mathur A; Meanwell NA; Gao M; Roberts SB; Kadow JF Bioorg Med Chem Lett; 2017 Aug; 27(15):3294-3300. PubMed ID: 28633899 [TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections. Beaulieu PL; Tsantrizos YS Curr Opin Investig Drugs; 2004 Aug; 5(8):838-50. PubMed ID: 15600240 [TBL] [Abstract][Full Text] [Related]
17. Diversity of the hepatitis C virus NS5B gene during HIV co-infection. Ngwaga T; Kong L; Lin D; Schoborg C; Taylor LE; Mayer KH; Klein RS; Celentano DD; Sobel JD; Jamieson DJ; King CC; Tavis JE; Blackard JT PLoS One; 2020; 15(8):e0237162. PubMed ID: 32750098 [TBL] [Abstract][Full Text] [Related]
18. Characterization of partial NS5B region among hepatitis C virus genotype 6 subtypes isolated from Thai blood donors. Chaiwong S; Sistayanarain A J Med Virol; 2016 Oct; 88(10):1785-90. PubMed ID: 27018495 [TBL] [Abstract][Full Text] [Related]
19. [Naturally occurring NS5B variants resistant to non-nucleoside or nucleoside polymerase inhibitors among treatment-naïve hepatitis C patients in south China]. Li Z; Liu Y; Cai Q; Shao X; Yan Y; Zhao Z Zhonghua Gan Zang Bing Za Zhi; 2015 Sep; 23(9):653-7. PubMed ID: 26524357 [TBL] [Abstract][Full Text] [Related]
20. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. Kukolj G; McGibbon GA; McKercher G; Marquis M; Lefèbvre S; Thauvette L; Gauthier J; Goulet S; Poupart MA; Beaulieu PL J Biol Chem; 2005 Nov; 280(47):39260-7. PubMed ID: 16188890 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]